证券代码：301111 证券简称：粤万年青 公告编号：2025-053 广东万年青制药股份有限公司 关于全资子公司转让下属控股公司股权暨关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、广东万年青制药股份有限公司（以下简称"公司"）全资子公司万年青 国际医疗管理（汕头）集团有限公司（以下简称"国际医疗"）与汕头市华银集 团有限公司（以下简称"华银集团"）、杭州贝康健康科技集团有限公司（以下 简称"杭州贝康"）签署《股权转让协议》，拟将其持有的汕头贝康恩泽健康管 理有限公司（以下简称"贝康恩泽"）60%股权转让给华银集团，转让价格为 1,200 万元；将其持有的贝康恩泽 10%股权转让给杭州贝康，转让价格为 200 万元。交 易完成后，国际医疗持有贝康恩泽的股权比例由 70%变更为 0%，贝康恩泽不再纳 入公司合并报表范围。 2、本次交易股权转让价格系以国际医疗对贝康恩泽已实缴的注册资本 1,400 万元为定价依据，交易完成后预计将增加公司本期净利润，具体会计处理及影响 数以会计师年度审计确认后的结果为准。 3、鉴于交易对手方之一华 ...

证券代码：301111 证券简称：粤万年青 公告编号：2025-051 广东万年青制药股份有限公司 第三届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、 董事会会议召开情况 广东万年青制药股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日 在公司会议室以现场和通讯表决的方式召开公司第三届董事会第九次会议，此前 公司于 2025 年 10 月 24 日及 2025 年 10 月 28 日以电子邮件形式向全体董事发出 会议通知和补充通知。会议由公司董事长欧先涛先生召集并主持，本次会议应出 席的董事 8 名，实际出席的董事 8 名（其中董事欧泽庆先生、颜文孟先生和独立 董事李华青先生、郭剑先生以通讯方式出席并行使表决权）。公司高级管理人员 列席了本次会议。 本次董事会会议的召集、召开和表决程序符合《中华人民共和国公司法》《中 华人民共和国证券法》等法律、法规及公司章程等相关规定。 二、董事会会议审议情况 经全体与会董事认真审议，形成以下决议： （一）审议通过了《关于公司 2025 年第三季度报告的议案》 具体内容详见 ...

Financial Performance - The company's revenue for Q3 2025 was ¥73,634,583.96, a decrease of 3.58% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥904,655.63, representing a 9.84% increase in loss year-over-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥2,576,218.08, an increase in loss of 29.08% compared to the previous year[5]. - The basic and diluted earnings per share were both -¥0.0056, reflecting an 11.11% improvement in loss compared to the same period last year[5]. - Total operating revenue for the current period was ¥228,414,862.64, a slight decrease from ¥228,744,341.01 in the previous period, representing a decline of approximately 0.14%[18]. - Net profit for the current period was a loss of ¥11,571,407.58, compared to a profit of ¥14,027,447.67 in the previous period, indicating a significant decline[19]. Assets and Liabilities - Total assets at the end of the reporting period were ¥925,406,528.97, a decrease of 0.83% from the end of the previous year[5]. - The company's total assets decreased to ¥925,406,528.97 from ¥933,166,569.41, reflecting a reduction of approximately 0.8%[17]. - Current assets increased to ¥534,992,432.67 from ¥515,196,124.27, showing a growth of about 3.5%[16]. - The company's total liabilities rose to ¥173,199,761.72 from ¥166,415,829.70, an increase of approximately 4.7%[17]. - The company's total equity attributable to shareholders decreased by 2.11% to ¥748,207,707.63 compared to the end of the previous year[5]. - The company's total equity decreased to ¥752,206,767.25 from ¥766,750,739.71, a decline of about 1.9%[18]. Cash Flow - The company's cash flow from operating activities showed a net outflow of -¥1,820,451.14, which is an improvement of 85.25% compared to the previous year[5]. - The net cash flow from operating activities improved by 85.25%, reaching -1,820,451.14, attributed to reduced cash payments for purchasing Chinese medicinal materials and increased collections from accounts receivable[9]. - Cash inflow from operating activities totaled 246,300,713.20 CNY, an increase from 229,823,388.87 CNY in the previous period, representing an increase of approximately 7.5%[20]. - Cash outflow from operating activities was 248,121,164.34 CNY, compared to 242,164,560.28 CNY in the previous period, resulting in a net cash flow from operating activities of -1,820,451.14 CNY, an improvement from -12,341,171.41 CNY[20]. - The net cash flow from investing activities decreased by 172.00%, totaling -10,584,071.39, primarily due to a reduction in the scale of redeeming financial products[9]. - Cash inflow from investment activities was 113,220,646.68 CNY, down from 161,551,091.36 CNY in the previous period, a decrease of approximately 29.9%[21]. - Cash outflow from investment activities totaled 123,804,718.07 CNY, compared to 146,850,820.49 CNY in the previous period, leading to a net cash flow from investment activities of -10,584,071.39 CNY, a decline from 14,700,270.87 CNY[21]. - The net cash flow from financing activities improved by 62.47%, amounting to -5,108,269.87, mainly due to decreased dividend distribution expenses[9]. - Cash inflow from financing activities was 5,170,000.00 CNY, an increase from 3,400,000.00 CNY in the previous period, representing a growth of approximately 52.2%[21]. - Cash outflow from financing activities was 10,278,269.87 CNY, down from 17,010,060.96 CNY in the previous period, resulting in a net cash flow from financing activities of -5,108,269.87 CNY, an improvement from -13,610,060.96 CNY[21]. Investments and Business Activities - The company established a new health management company with a registered capital of RMB 1 million, holding a 19% stake, focusing on health diagnosis services[13]. - The company formed a joint venture for ophthalmic diagnosis services with a registered capital of RMB 2 million, also holding a 19% stake[13]. - The company transferred 100% equity of Jiangxi Yuanqifu Pharmacy Chain Co., Ltd. for RMB 750,000, which will no longer be included in the consolidated financial statements[14]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,433[11]. - The largest shareholder, Guangdong Jino Health Technology Co., Ltd., holds 45.00% of the shares, amounting to 72,000,000 shares[11]. Expenses and Financial Management - Financial expenses increased by 162.77% to ¥987,915.22 due to new business expansion and increased rental costs[8]. - Investment income decreased by 55.49% to ¥3,728,443.65, primarily due to reduced idle funds available for investment and losses from joint ventures[8]. - The fair value change income decreased by 70.51%, amounting to 461,965.43, primarily due to reduced idle funds available for financial management as the company expanded new businesses[9]. - Credit impairment losses increased by 122.28%, totaling -291,888.35, mainly due to an increase in accounts receivable leading to higher bad debt provisions[9]. - Research and development expenses for the current period were ¥6,675,637.43, slightly up from ¥6,416,666.62 in the previous period[18]. Audit Information - The company did not undergo an audit for the third quarter financial report[22].

证券代码：301111 证券简称：粤万年青 公告编号：2025-050 广东万年青制药股份有限公司 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 广东万年青制药股份有限公司（以下简称"公司"）于 2025 年 7 月 4 日在 巨潮资讯网（www.cninfo.com.cn）披露了《关于控股股东、实际控制人的一致 行动人股份减持计划的预披露公告》 （公告编号：2025-031），股东汕头市银 康企业管理咨询合伙企业（有限合伙）（以下简称"银康管理"）计划自该公告 披露之日起十五个交易日后的三个月内以集中竞价交易、大宗交易方式合计减持 公司股份不超过 4,800,000 股，即减持比例不超过公司总股本的 3.00%。 近日，公司收到银康管理出具的《告知函》,获悉银康管理于 2025 年 10 月 22 日，通过集中竞价及大宗交易的方式累计减持公司股份 2,915,900 股，占公司 总股本的比例为 1.8224375%。本次减持后，控股股东金欧健康及其一致行动人侨 银房地产、银康管理合计持有公司股份 85,061,520 股，占公司总股本的比例为 53.16345%,权益变动触及公司总股 ...

Group 1 - The core transaction involved 2.8 million shares of Yue Wannianqing, with a total transaction value of 40.404 million yuan, accounting for 37.98% of the total trading volume on that day [1][2] - The transaction price was 14.43 yuan per share, which represents a discount of 16.4% compared to the market closing price of 17.26 yuan [1][2]

证券代码：301111 证券简称：粤万年青 公告编号：2025-049 广东万年青制药股份有限公司 关于使用部分闲置募集资金（含超募资金）和自有资金进行 现金管理到期赎回并继续进行现金管理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广东万年青制药股份有限公司（以下简称"公司"）于 2024 年 12 月 18 日 召开第三届董事会第四次会议，并于 2025 年 1 月 3 日召开 2025 年第一次临时 股东大会，审议通过了《关于使用部分闲置募集资金（含超募资金）和自有资 金进行现金管理的议案》，同意公司在确保不影响正常运营和募集资金投资项目 建设的情况下，使用不超过人民币 2.5 亿元（含 2.5 亿元）的闲置募集资金 （含超募资金）及不超过人民币 2.5 亿元（含 2.5 亿元）的自有资金进行现金 管理，上述额度自股东大会审议通过之日起 12 个月内有效。在上述额度和期限 范围内，资金可循环滚动使用，并授权公司管理层在额度范围内行使相关决策 权、签署相关合同文件等。具体内容详见公司于 2024 年 12 月 19 日及 2025 年 1 月 3 ...

Market Overview - The Shanghai Composite Index is at 3916.86 points, above the annual line, with a change of 0.12% [1] - The total trading volume of A-shares is 909.4 billion yuan [1] Stocks Breaking Annual Line - A total of 20 A-shares have surpassed the annual line today, with notable stocks including: - Shenglong Co., Ltd. (603178) with a deviation rate of 9.96% - Lege Co., Ltd. (300729) with a deviation rate of 2.14% - Jinguang Co., Ltd. (300510) with a deviation rate of 1.75% [1] Deviation Rate Rankings - The following stocks have the highest deviation rates after breaking the annual line: - Shenglong Co., Ltd. (603178): Today's change of 10.00%, turnover rate of 4.72%, latest price at 21.45 yuan [1] - Lege Co., Ltd. (300729): Today's change of 4.01%, turnover rate of 4.10%, latest price at 15.58 yuan [1] - Jinguang Co., Ltd. (300510): Today's change of 2.00%, turnover rate of 5.62%, latest price at 4.60 yuan [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the annual line include: - Changjiang Electric Power (600900): Today's change of 0.36%, latest price at 28.03 yuan, deviation rate of 0.01% [2] - Beiqi Blue Valley (600733): Today's change of 3.05%, latest price at 8.11 yuan, deviation rate of 0.03% [2] - Hongcheng Environment (600461): Today's change of 0.22%, latest price at 9.10 yuan, deviation rate of 0.05% [2]

Core Insights - On October 9, Guangdong Wannianqing Pharmaceutical Co., Ltd. experienced a slight increase in stock price by 0.06%, with a trading volume of 40.6182 million yuan [1] - The company reported a net financing purchase of 4.2516 million yuan on the same day, indicating strong investor interest despite a high financing balance [1][2] Financing and Margin Trading - On October 9, the financing buy amount was 8.1348 million yuan, while the financing repayment was 3.8832 million yuan, resulting in a net financing purchase of 4.2516 million yuan [1] - The total financing and margin trading balance reached 63.0634 million yuan, accounting for 2.53% of the circulating market value, which is above the 70th percentile of the past year [1] - There were no shares sold or repaid in the margin trading segment, with a margin balance of 0.00 yuan, indicating a high level of investor confidence [1] Company Overview - Guangdong Wannianqing Pharmaceutical Co., Ltd. was established on March 16, 1981, and went public on December 7, 2021 [1] - The company's main business involves the research, production, and sales of traditional Chinese medicine, with revenue composition as follows: 91.17% from pharmaceuticals, 5.96% from medical services and health management, 2.23% from medicinal slices, and 0.64% from other sources [1] - As of June 30, the number of shareholders decreased by 7.90% to 12,300, while the average circulating shares per person increased by 8.57% to 12,989 shares [2] Financial Performance - For the first half of 2025, the company achieved a revenue of 155 million yuan, reflecting a year-on-year growth of 1.58% [2] - The net profit attributable to the parent company was -7.2249 million yuan, representing a significant year-on-year decrease of 147.83% [2] - Since its A-share listing, the company has distributed a total of 65.6 million yuan in dividends, with 40 million yuan distributed over the past three years [2]

Group 1 - The core point of the article is that Shantou Yinkang Enterprise Management Consulting Partnership (Limited Partnership) has reduced its stake in Guangdong Wan Nian Qing by selling 1.8841 million shares, which represents 1.1775625% of the company's total share capital [1] - After this equity change, the controlling shareholder, Guangdong Jinou Health Technology Co., Ltd., along with its concerted parties, holds a total of 87.9774 million shares, accounting for 54.9858875% of the company's total share capital [1]

证券代码：301111 证券简称：粤万年青 公告编号：2025-048 广东万年青制药股份有限公司 公司控股股东广东金欧健康科技有限公司及其一致行动人广东侨银房地产 开发有限公司、汕头市银康企业管理咨询合伙企业（有限合伙）保证向本公司 提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 1、本次权益变动性质为控股股东、实际控制人的一致行动人汕头市银康企 业管理咨询合伙企业（有限合伙）（以下简称"银康管理"）持股比例减少，不触 及要约收购，不会导致公司的控股股东和实际控制人发生变化，不会对公司治理 结构及持续经营产生影响。 2、本次权益变动后，公司控股股东、实际控制人及其一致行动人合计持有 公司股份 87,977,420 股，占公司总股本的比例为 54.9858875%，权益变动触及公 司总股本 5%的整数倍。 一、本次权益变动的基本情况 公司于 2025 年 7 月 4 日在巨潮资讯网（www.cninfo.com.cn）披露了《关于 控股股东、实际控制人之一致行动人股份减持计划的预披露公告》 （公告编号： 2 ...